EZH2 and pulmonary arterial hypertension: Elevated EZH2 levels in pulmonary arterial hypertension (PAH) patients can be targeted with GSK126, demonstrating decreased PASMC proliferation and improved mitochondrial function in vitro (Habbout et al., 2021; Dave et al., 2023).